Skip to main content
. 2024 Jun 15;16(6):2504–2519. doi: 10.4251/wjgo.v16.i6.2504

Table 3.

Subgroup analysis of tumour response according to whether or not they received antiviral therapy, n (%)


Antiviral therapy (no), n = 25
Antiviral therapy (yes), n = 95
HBV-DNA (HBV > 2000), n = 8
HBV-DNA (HBV ≤ 2000), n = 18
P value
HBV-DNA (HBV > 2000), n = 46
HBV-DNA (HBV ≤ 2000), n = 48
P value
PR 2 (29) 3 (17) 0.597 15 (32) 10 (21) 0.220
SD 3 (43) 11 (61) 0.656 18 (38) 24 (50) 0.251
PD 2 (29) 4 (22) > 0.999 14 (30) 14 (29) 0.947
ORR 2 (29) 3 (17) 0.597 16 (34) 10 (21) 0.149
DCR 5 (71) 14 (78) > 0.999 35 (74) 34 (71) 0.691
ORR (whole) 5 (20) - 26 (27) 0.454
DCR (whole) 6 (24) - 26 (27) 0.735

Data in brackets represent the percentages of patients. HBV: Hepatitis B virus; PR: Partial responds; SD: Stable disease; PD: Progression disease; ORR: Objective responds rates; DCR: Disease control rates.